MARKET

CCXI

CCXI

ChemoCentryx
NASDAQ

Real-time Quotes | Nasdaq Last Sale

57.24
+0.03
+0.05%
After Hours: 57.24 0 0.00% 16:01 03/05 EST
OPEN
58.44
PREV CLOSE
57.21
HIGH
58.71
LOW
55.27
VOLUME
596.16K
TURNOVER
--
52 WEEK HIGH
70.29
52 WEEK LOW
30.72
MARKET CAP
3.98B
P/E (TTM)
-67.9487
1D
5D
1M
3M
1Y
5Y
Diabetic Nephropathy Market 2016-2026 Global Analysis, Size, Share, Incredible Growth, Detailed Industry Analysis and Business Prospects | FMI
Mar 04, 2021 (MARKITWIRED via COMTEX) -- VALLEY COTTAGE, N.Y. -Impact of COVID-19 on the Healthcare Industry The COVID-19 pandemic has causedsevere impacts...
Markitwired · 1d ago
Analysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI), Itamar Medical (ITMR) and Neurocrine (NBIX)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on ChemoCentryx (CCXI), Itamar Medical (ITMR) and Neurocrine (NBIX).
SmarterAnalyst · 1d ago
8-K: ChemoCentryx, Inc.
(EDGAR Online via COMTEX) -- false 0001340652 0001340652 2021-02-25 2021-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Edgar Online - (EDK = 8-Ks/S1/S-4) · 2d ago
ChemoCentryx, Inc.'s (NASDAQ:CCXI) Profit Outlook
ChemoCentryx, Inc. ( NASDAQ:CCXI ) is possibly approaching a major achievement in its business, so we would like to...
Simply Wall St. · 2d ago
ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss
Zacks.com · 2d ago
DJ ChemoCentryx Initiated at Buy by Stifel
Dow Jones · 3d ago
DJ ChemoCentryx Price Target Announced at $93.00/Share by Stifel
Dow Jones · 3d ago
ChemoCentryx (CCXI) Q4 Loss Wider Than Expected, Sales Miss
Zacks.com · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CCXI. Analyze the recent business situations of ChemoCentryx through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CCXI stock price target is 88.88 with a high estimate of 120.00 and a low estimate of 70.00.
EPS
Institutional Holdings
Institutions: 298
Institutional Holdings: 58.27M
% Owned: 83.70%
Shares Outstanding: 69.61M
TypeInstitutionsShares
Increased
80
3.35M
New
65
954.99K
Decreased
61
2.79M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+1.51%
Pharmaceuticals & Medical Research
+1.63%
Key Executives
Chairman/Chief Executive Officer/President/Director
Thomas Schall
Chief Financial Officer/Executive Vice President/Chief Administrative Officer/Secretary/IR Contact Officer
Susan Kanaya
Chief Operating Officer/Executive Vice President
Tausif Butt
Treasurer
Markus Cappel
Independent Director
Thomas Edwards
Independent Director
Joseph Feczko
Independent Director
Rita Jain
Independent Director
Henry McKinnell
Independent Director
Geoffrey Parker
Independent Director
James Tyree
No Data
  • All
  • Financials
  • Insiders
More
About CCXI
ChemoCentryx, Inc. is a biopharmaceutical company. The Company is engaged in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of its drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. Its late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS).

Webull offers kinds of ChemoCentryx Inc stock information, including NASDAQ:CCXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CCXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CCXI stock methods without spending real money on the virtual paper trading platform.